Seung-Il Park

Seung-Il Park

Auto-generated profile, based on publicly available information

Seung-Il Park

Department of Thoracic and Cardiovascular Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2019 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
JYJae Kwang Yun
Jae Kwang Yun
GLGeun Dong Lee
Geun Dong Lee
SCSehoon Choi
Sehoon Choi
HKHyeong Ryul Kim
Hyeong Ryul Kim
YKYong-Hee Kim
Yong-Hee Kim
SPSeung-Il Park
Seung-Il Park
OBJECTIVES: The International Association for the Study of Lung Cancer (IASLC) proposed further subdivisions of pathological N1 (pN1) and pN2 by including the location and the number of involved lymph node (LN) stations. We adopted the subdivided N descriptors and reclassified them according to the involved LN zones or LN stations, and compared the discrimination abilities of the 2 classifications.METHODS: A retrospective analysis was carried out on patients who underwent complete resection with systematic LN dissection for non-small cell lung cancer diagnosed as pathological stages I–III between 2006 and 2015. N classification was grouped into 6 categories: no LN involvement, single-station N1, multiple-station N1, single-station N2 without N1, single-station N2 with N1 and multiple-station N2. LN zones were defined by grouping the LN stations: peripheral or hilar for N1 nodes, and upper mediastinal, lower mediastinal, aortopulmonary and subcarinal for N2 nodes.RESULTS: A total of 3971 patients (2451 men, median age: 63 years) were analysed. Median follow-up was 59 months. A multivariable analysis showed that the subdivided N descriptors based on LN station and zone were both independent prognostic factors in terms of both overall survival and freedom from recurrence. Whether multiple LN involvements were confined within a single LN zone was a significant prognostic factor in the multiple-station N2 group. A zone-based classification showed similar discrimination ability to the station-based classification.CONCLUSIONS: Both LN station- and zone-based classifications showed favourable prognostic discrimination abilities. The new N classifications could be considered for future revisions of tumour, node and metastasis (TNM) staging system for lung cancer.

10 March 2020 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
JYJae Kwang Yun
Jae Kwang Yun
JBJin San Bok
Jin San Bok
GLGeun Dong Lee
Geun Dong Lee
HKHyeong Ryul Kim
Hyeong Ryul Kim
YKYong-Hee Kim
Yong-Hee Kim
SCSehoon Choi
Sehoon Choi
OBJECTIVES: Although the standard treatment for pathological N2 (pN2) non-small-cell lung cancer (NSCLC) patients is definitive chemoradiation, surgery can be beneficial for resectable pN2 disease. Herein, we report the long-term clinical outcomes of upfront surgery followed by adjuvant treatment for selected patients with resectable pN2 disease. METHODS: We performed a retrospective analysis of clinical outcomes for patients with pN2 disease who underwent surgery as the first-line therapy. Multivariable Cox regression analysis was used to identify the significant factors for overall survival (OS) and recurrence-free survival. RESULTS: From 2004 to 2015, a total of 706 patients with pN2 NSCLC underwent complete anatomical resection at our institution. The patients’ clinical N stages were cN0, 308 (43.6%); cN1, 123 (17.4%) and cN2, 275 (39.0%). Adjuvant chemotherapy, radiotherapy and chemoradiotherapy were administered to 169 (23.9%), 115 (17.4%) and 299 patients (42.4%), respectively. With a median follow-up of 40 months, the respective median time and 5-year rate of OS were 52 months and 44.7%. According to subdivided pN2 descriptors, the median OS time was 80, 53 and 37 months for patients with pN2a1, pN2a2 and pN2b, respectively. Adjuvant chemotherapy was a significant prognostic factor for both OS [hazard ratio (HR) 0.39, 95% confidence interval (CI) 0.28–0.52; P < 0.001] and recurrence-free survival (HR 0.42, 95% CI 0.30–0.58; P < 0.001). CONCLUSIONS: Upfront surgery followed by adjuvant therapy for resectable N2 disease showed favourable outcomes compared to those reported in previous studies. Adjuvant chemotherapy is essential to improve the prognosis for patients undergoing upfront surgery for N2 disease.

4 December 2017 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
HJHyoung Uk Je
Hyoung Uk Je
SSSi Yeol Song
Si Yeol Song
DKDong Kwan Kim
Dong Kwan Kim
YKYong-Hee Kim
Yong-Hee Kim
SJSeong-Yun Jeong
Seong-Yun Jeong
ECEun Kyung Choi
Eun Kyung Choi
To evaluate the role of radiotherapy (RT) as an adjuvant or definitive treatment in primary tracheal adenoid cystic carcinoma (ACC) for local tumor control and survival. A retrospective chart review was performed in 22 patients treated with adjuvant or definitive RT for primary tracheal ACC at a single center between November 1994 and December 2008. Thirteen and 9 patients received adjuvant and definitive RT, respectively. Microscopic residual disease after surgery was pathologically reported in 11 patients. The median RT dose was 59.4 Gy for adjuvant and 74.4 Gy for definitive RT. The overall response rate for definitive RT was 77.8%. Six patients in the definitive RT group exhibited local progression (LP), whereas 14 patients in both groups exhibited distant metastasis. The most common recurrence site in cases of treatment failure was the lung parenchyma. The median follow-up duration was 123 months, and the 10-year overall survival (OS) rate was 54.2%. Although LP was the most common cause of death (4 patients), two-thirds of the patients treated with definitive RT lived for >5 years. The 5-year and 10-year LP-free survival (LPFS) rates in the definitive RT group were 66.7 and 26.7%, respectively. Patients with higher RT dose by brachytherapy boost had good 5-year OS, 83.3%, and showed no local progression till 5-years. Most of the RT-induced side-effects were mild and tolerable, but 2 patients died of tracheal stenosis without any tumor recurrence. Adjuvant RT may be suitable for controlling microscopic residual disease, whereas definitive RT may yield appropriate long-term survival in >50% patients with unresectable tracheal ACC. Dose escalation should be considered to warrant long-term survival in definitive RT.

1 May 2018 in Transplantation
Verified
Journal Article
Closed access
YCYoujin Chang
Youjin Chang
SLSang Oh Lee
Sang Oh Lee
TSTae Sun Shim
Tae Sun Shim
SCSae Hoon Choi
Sae Hoon Choi
HKHyung Ryul Kim
Hyung Ryul Kim
SPSeung-Il Park
Seung-Il Park
Background Lung transplantation (LTPL) is considered as a salvage therapeutic option in patients with end-stage lung disease. However, there is a lack of sufficient data on the use of LTPL in patients with acute respiratory distress syndrome (ARDS). Although there are few case reports on lung transplant for ARDS, no case series exists up to date. The aim of this study was to evaluate the clinical outcomes of patients with ARDS in accordance with the LTPL status. Methods Patients who had severe ARDS (PaO2/FiO2 ratio ≤ 100 mm Hg with positive end-expiratory pressure ≥ 5 cm H2O) and were listed for LTPL with no underlying end-stage lung disease were included in this single-center retrospective study. Demographic and clinical data of the patients were collected and analyzed. Results Fourteen patients were listed for LTPL due to severe ARDS. All patients received mechanical ventilation, and 12 (86%) patients underwent extracorporeal membrane oxygenation. Of the 9 patients who underwent LTPL, 8 (89%) survived, whereas only 1 (20%) patient out of those who did not receive LTPL survived. The median survival time of the patients who underwent LTPL was 1996 days (interquartile range [IQR], 872-2239), compared with 49 days (IQR, 872-2239) in patients who did not undergo LTPL. The median survival time after LTPL was 64 months (IQR, 28-72). The 3-year survival rate of the recipients was 78%. Conclusions LTPL may be considered as a therapeutic option in a select group of patients with severe ARDS. However, the irreversibility of the patient's lung status should be considered.

31 May 2020 in Acute and Critical Care
Verified
Journal Article
Open access
PDF file
DODong Kyu Oh
Dong Kyu Oh
TSTae Sun Shim
Tae Sun Shim
KJKyung-Wook Jo
Kyung-Wook Jo
SPSeung-Il Park
Seung-Il Park
DKDong Kwan Kim
Dong Kwan Kim
SHSang-Bum Hong
Sang-Bum Hong
Right heart decompensation is a fatal complication in patients with respiratory failure, particularly in those transitioned to lung transplantation using veno-venous extracorporeal membrane oxygenation (V-V ECMO). In these patients, veno-arterial (V-A ECMO) or veno-arterialvenous extracorporeal membrane oxygenation (V-AV ECMO) is used to support both cardiac and respiratory function. However, these processes may increase the risk of device-related complications such as bleeding, thromboembolism, and limb ischemia. In the present case, a 64-year-old male patient with idiopathic pulmonary fibrosis developed respiratory failure and commenced treatment with V-V ECMO as a bridge to lung transplantation. Unfortunately, the patient developed right heart decompensation and required both cardiac and respiratory support during treatment with V-V ECMO. Instead of adding arterial cannulation, he was switched to a novel configuration, a right ventricular assist device with an oxygenator (Oxy- RVAD) using ECMO, with drainage cannulation from the femoral vein and return cannulation to the main pulmonary artery. The patient was successfully bridged to lung transplantation without serious complications after 10 days of Oxy-RVAD support. To the best of our knowledge, this is an extreme rare and challenging case of Oxy-RVAD using ECMO in a patient successfully bridged to lung transplantation.

31 July 2010 in The Journal of Thoracic and Cardiovascular Surgery
Verified
Journal Article
Closed access
JKJoon-bum Kim
Joon-bum Kim
SLSei Won Lee
Sei Won Lee
SPSeung-Il Park
Seung-Il Park
YKYong Hee Kim
Yong Hee Kim
DKDong Kwan Kim
Dong Kwan Kim